Physician profile
Harry Drummond
NPI 1164416517
$6,191.69
in general payments reported to CMS, 2019-2025
35 companies · $16.26 in 2025
The $16.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $1,081 · 2021: $1,525 · 2022: $1,330 · 2023: $708 · 2024: $40.57 · 2025: $16.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,037.10 | 2019-2023 | Rybelsus, Ozempic, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $832.44 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $822.74 | 2019-2023 | Farxiga |
| Abbvie INC. | $585.10 | 2019-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $295.20 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $261.12 | 2019-2023 | Jardiance, Mounjaro |
| Amgen INC. | $224.56 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.73 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $197.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $166.15 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $150.69 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $136.02 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $135.39 | 2020-2021 | |
| Allergan, INC. | $127.63 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $105.31 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $99.24 | 2023 | Quviviq |
| Lundbeck LLC | $68.64 | 2020-2021 | |
| Gilead Sciences, INC. | $61.37 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $49.92 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.73 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $47.11 | 2021-2022 | |
| Eisai INC. | $39.84 | 2020 | |
| Astellas Pharma US INC | $36.54 | 2019 | |
| Pfizer INC. | $35.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.60 | 2019-2022 | |
| Dynavax Technologies Corporation | $25.50 | 2022 | |
| Vertiflex, INC. | $20.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.98 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.71 | 2024 | Caplyta |
| Dermira, INC. | $17.46 | 2020 | |
| Abbott Laboratories | $16.66 | 2019 | |
| Apria Healthcare LLC | $15.67 | 2021 | |
| Phadia US INC. | $15.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Drummond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.